Title |
Étude de phase III: Radiothérapie par modulation d'intensité préopératoire VS post-opératoire pour les sarcomes des tissus mous du tronc et des extrémités. |
Protocole ID |
RxTx 50/50 |
ClinicalTrials.gov ID |
n.d. |
Cancer Type(s) |
Sarcoma |
Phase |
Phase III |
Stage |
|
Study Type |
Treatment |
Drug |
|
Institution |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
5415 boul. de l'Assomption, Montréal, QC, H1T2M4
|
City |
Montréal |
Principal Investigator |
Dr. Nader Khaouam
|
Coordinator |
Jany Barry
514-252-3400
|
Status |
Recruiting |
Activation Date |
|
Eligibility Criteria |
- Histologically proven soft tissue sarcoma of the extremity or trunk following review by local reference pathologist.
- Deemed appropriate for preoperative or postoperative radiotherapy and conservative surgery following patient assessment by a radiation oncologist and surgical oncologist.
- Lesion is primary or locally recurrent. Patient may have undergone excisional biopsy with positive margins at a referring hospital and are eligible following discussion among the surgical oncologists and radiation oncologists that IMRT is an acceptable treatment for that case.
- ECOG 0-3
- Patient is aged 18 years or older.
- Patient is able to provide informed consent
- Patient is available for treatment and follow-up.
|
Exclusion Criteria |
- Benign histology.
- Prior malignancy within the previous five years or concurrent malignancy with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in-situ of the cervix.
- Prior radiotherapy to the target site
- Planned chemotherapy for (neo)adjuvant treatment
- Conservative surgery to the target site only
- Presence of regional nodal disease or unequivocal distant metastases.
- Other major medical illness deemed to preclude safe administration of protocol treatment or required follow-up.
|
|
|